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 BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE 
ESTIMATION OF TENOFOVIR DISOPROXIL FUMARATE AND LAMUVIDINE IN 
HUMAN PLASMA BY USING RP-HPLC 
Abstract: A simple reverse-phase high-performance liquid chromatographic method for the 
estimation of tenofovir disoproxil fumarate and lamivudine in human plasma samples has been 
developed and validated. The assay of the drugs was performed on a Phenomenex C18 Column with UV 
detection at 259 nm. The mobile phase consisted of 0.05% Heptane sulphonic acid: acetonitrile in the 
ratio of 80:20, and a flow rate of 1 ml/min was maintained. Linearity in the range of 200-1000 ng/ml for 
Tenofovir (r2=0.998) and that of Lamivudine was found to be 200 to 1000ng/ml (r2=0.998). Analytic 
parameters have been evaluated. Intra-day and inter-day precision as expressed by relative standard 
deviation was found to be less than 2%. The method has been applied successfully for the estimation of 
tenofovir disoproxil fumarate and lamivudine in spiked human plasma samples.  
Keywords: Lamivudine, Tenofovir disoproxil fumerate, high-performance liquid 
chromatographic 
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I. INTRODUCTION 1-11 
 
The assay methods must be able to withstand the scrutiny of national drug registration 
authorities who judge them on the basis of criteria established by international consensus.   
      In bioanalytical chemistry the qualitative and quantitative analysis of drug substances in 
biological fluids (mainly plasma and urine) or tissue was carried out .It play a significant role for 
the evaluation and interpretation of bioavailability, bioequivalence and pharmacokinetic data
1
. 
The main analytical phases that comprises bioanalytical services are, 
 Method development 
 Method validation 
 Sample analysis  
       Owing to increased independence among countries in recent times it has become necessary 
for results of many analytical methods to be accepted internationally. Consequently, to assure a 
common level of quality, the need for and use of validated methods has increased
2
. 
           A full validation requires a high workload and should therefore only start when promising 
results are obtained from explorative validation performed during the method development 
phase
3
. The process of being validate a method cannot be separated from the actual development 
conditions, because the developer will not known whether the method conditions were being 
acceptable until validation studies are performed
4
 . Method development clears the way for the 
further process on the validation stage. However, this effort is repaid by the time saved when 
running method routinely during sample analysis. 
1.0. METHOD DEVELOPMENT. 
A bioanalytical method is a set of all of the procedure involved in the collection, processing, 
storing, and analysis of a biological matrix for an analyte
5
. Analytical methods employed for 
quantitative determination of drug and their metabolites in biological fluids are the key 
determinants in generating reproducible and reliable data that in turn are used in the evaluation 
and interpretation of bioavailability, bioequivalence and pharmacokinetics
6
. 
          Method development involves evaluation and optimization of the various stages of sample 
preparation, chromatographic separation, detection and quantification. To start these work an 
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extensive literature survey, reading work done on the same or similar analyte and summarizing 
main starting points for future work is of primary importance. Based on the information from the 
survey, the following can be done. 
 Choice of instrument that is suitable for the analysis of analyte of interest. 
 Choice of the column associated with instrument of choice, the detector and the mobile 
phase. 
 Choice of internal standard, (It must have similar chromatographic properties of 
analyte).  
 Choice of extraction procedure (which is time economical, gives the highest possible 
recovery without interferences and has acceptable accuracy and precision).  
 
              Another   important issue in method development stage is the choice of internal      
versus external standardization is common in bioanalytical methods especially with 
chromatographic procedures .For internal standardization, a structural or isotopic analogue of the 
analyte is added to the sample prior to sample pre-treatment and the ratio of the response of 
analyte to that of the internal standard is plotted against the concentration
7
. Another important 
point is that the tests performed at the stage of method development be done with same 
equipment that will actually be used for subsequent routine analysis. 
1.1. BIOPHARMACEUTICAL ANALYSIS  
1.1.1. Need for biopharmaceutical analysis 
      Methods of measuring drugs in biological media are increasingly important related to 
following; 
 Bioavailability and bioequivalence studies 
 New drug development 
 Clinical pharmacokinetics 
 Research in Basic Biomedical and Pharmaceutical Sciences. 
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1.2 ASSAY OF DRUGS AND THEIR METABOLITES 
       A number of allusions have been made to analytical methods that distinguish drugs from 
their metabolites. Drug metabolism can be divided into phase I and phase II transformation 
condensation of drugs or their phase I metabolites with common body constituents (sulfate, 
glucuronic acid). 
       This involves glucoronidation, sulfation, amino acid conjugation, acetylation and 
methylation. Except for reduction processes, most phase I and phase II reactions yield 
metabolites that are more polar and hence more water soluble than parent drug.  Assay must 
distinguish between drug and its metabolites. If this fact is ignored, erroneous data may be 
generated. 
1.3. ANALYSIS OF DRUG IN VARIOUS BIOLOGICAL MEDIA  
       The most common samples obtained for biopharmaceutical analysis are blood, urine, and 
feces, especially if the drug or metabolite is poorly absorbed or extensively excreted in the bile. 
Other media that can be utilized includes saliva, breath and tissue. 
       The choice of sampling media is determined largely by the nature of   used in the study. For 
example, drug levels in a clinical pharmacokinetic study demand the use of blood, urine, and 
saliva. A bioavailability study may require drug level data in blood and / or urine whereas a drug 
identification or drug abuse problem may be solved with only one type of biological sample. 
       Detection of drug or its metabolite in biological media is usually complicated by the matrix. 
Because of this, various types of cleanup procedures involved i.e. solvent extraction and 
chromatography are employed to effectively separate drug components form endogenous 
biological materials. The sensitivity and selectivity of the assay method was limited by the 
efficiency of the clean up methodology. 
       If the blood is allowed to clot and is then centrifuged, about 30 to 50% of the original 
volume is collected as serum (upper level). Thus, plasma generally is preferred because of its 
greater yield from blood. Blood, serum or plasma samples can be utilized for bioanalytical 
studies and may require protein denaturation steps before further processes. 
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         If plasma or serum is used for the analytical procedure, the fresh whole blood should be 
centrifuged immediately at 5000 rpm for approximately 5 to 10 min, and the supernatant should 
be transferred by means of a suitable device, such as pasture pipette, to a clean container of 
appropriate size of storage. 
       Urine is the easiest one to obtain from the patient and also permits collection of large and 
frequently more concentrated samples. The lack of protein in a healthy individual‟s urine 
obviates the need for denaturation steps, because urine samples are readily obtained and often 
provide the greatest source of metabolites, they are frequently analyzed in drug metabolism 
studies. 
1.4 STORAGE REQUIREMENTS FOR BIOLOGICAL SAMPLES 
       In order to avoid decomposition or other potential chemical changes in the drugs to be 
analyzed, biological samples should be frozen immediately upon collection and thawed before 
analysis. When drugs are susceptible to plasma esterase, the addition of esterase inhibitors, such 
as sodium fluoride was immediately added after collection helps to prevent decomposition. 
       When collecting and storing biological samples, the analyte should be contaminated with 
storage vessels. For example, plastic –ware frequently contains high boiling liquid bis (2-
ethylhexyl) phthalate; similarly, the plunger-plugs of vacutainers are known to contain tri-
butoxyethyl phosphate, which can be interfere with certain drug analysis. 
1.5 BIOANALYTICAL METHODOLOGY 
The bioanalytical methods used to determine the drug and/or its metabolites in the 
plasma, serum, blood or urine or any other suitable matrix must be well characterized, 
standardized, fully validated and documented to yield suitable results that can be satisfactorily 
interpreted. 
      Although there are various steps in the development and validation of an analytical 
procedure, the validation of the analytical method can be envisaged to be to consist of two 
distinct phases: 
Dept of pharmaceutical Analysis                                                                               Introduction                                                                                                                                                                                    
 
KMCH College Of Pharmacy Page 5 
 
      a) The pre-study phase which comes before the actual start of the study and involves the 
validation of the method on biological matrix human plasma samples and spiked plasma 
samples. 
b) The study phase in which the validated bioanalytical method is applied to the actual 
analysis of the samples from bioavailability and bioequivalence studies mainly to confirm the 
stability, accuracy and precision
9
. 
1.5.1. Pre-studies Phase 
The following features of the bioanalytical method must be evaluated and documented to 
ensure the acceptability of the performance and reliability of analytical results.  
 Stability of the drug metabolite in the matrix: 
Stability of the drug and/or its active metabolite in the biological matrix under the 
conditions of the experiment (including any period for which samples are stored before analysis) 
should be established. The stability data should also include the influence of at least three 
freezing and thawing cycle‟s representatives of actual sample handling. The absence of any 
sorption by the sampling containers and stoppers should also be established. 
 Specificity/ selectivity: 
Data should be generate to demonstrated that the assay does not suffer from the 
interference by the endogenous compounds, degradation products, other drugs likely to be 
present in study samples, and metabolites of drug(s) under study. 
 Sensitivity: 
  Sensitivity is the capacity of the test procedure to record the small variations in 
concentration. The analytical method chosen should be capable of assaying the drug/metabolites 
over the expected concentration range. A reliable lowest limit of quantification should be 
established based on an intra-and inter- day coefficient of variation usually not greater than 20 
percent. The limit of detection (the lowest concentration that can be differentiated from 
background levels) is usually lower than the limit of quantification and the limit of detection 
should be identified as, “Below Quantification Limits.” 
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 Precision and Accuracy: 
  Precision (the degree of reproducibility of individual assays) should be established by 
replicate assays on standards, preferably at several concentrations. Accuracy is the degree to 
which the „true‟ value of concentration of drug is estimated by the assays. Precision and accuracy 
should normally be documented at three concentrations (low, medium, high) where „low‟ is in 
the vicinity  of the lowest concentration to be measured , „high‟ is a value in the vicinity of the 
Cmax  and the „medium‟ is a suitable intermediate value. 
             Intra-assay precision (within days) in terms of coefficients of variation should be no 
more than 15%, although no more than 20% may be more realistic  at values near  the lower limit 
of quantification. Inter-assay precision (between days) may be higher than 15% but not more 
than 20%.  
            Accuracy can be accessed in conjunction and precision and is a measure of extent to 
which measured concentration deviates from true or nominal concentrations of analytical 
standards. In general, an accuracy of ± 15% should be attended.  
 Recovery: 
Documentation of extraction recovery at high, medium and low concentrations is 
essential because methods with low recovery are, in general, more prone to inconsistency. If 
recovery was low, alternative methods were investigated. Recovery of any internal standard used 
should also be accessed. 
 Range and Linearity: 
    The quantitative relationship between concentration and response should be adequately 
characterized over the entire range of expected sample concentrations. For linear relationships, a 
standard curve should be defined by at least five concentrations .if the concentration response 
function was found to be non-linear, additional points would be necessary for the non-linear 
portions of the curve. Extrapolation beyond the standard curve was not acceptable. 
 Analytical System Stability: 
          To ensure that the analytical system remains stable over the time course of the assay, the 
reproducibility of the standard curve should be monitored during the assay. A minimal 
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requirement would be to run analytical standards at the beginning and at the end of the analytical 
run
8
.    
1.5.2. Study Phase 
In general, with suitable variability as defined by validation data, the analysis of 
biological sample can be done by single determination without a need for a duplicate or replicate 
analysis. The needs for duplicate analysis should be assessed on a case by case basis. A 
procedure should be developed that document the reasons for re-analysis. 
          A standard curve should be generated for each analyte and used to calculate the 
concentration of analyte in the unknown sample assayed with that run. It is important to use a 
standard curve that will cover the entire range of concentration in unknown samples. Estimation 
of unknown samples by extrapolation of standard curves below the lowest standard concentration 
or above the highest standard concentration is should be re-assayed after dilution.  
1.7. EXTRACTION PROCEDURE FOR BIOLOGICAL SAMPLE 
  After pre treating biological material, the next step is usually the extraction of the drugs 
from the biological matrix. All separation procedures used one or more treatments of matrix – 
containing solute with some fluid. If the component are a liquid (extracting solvents) and a solid 
(e.g., lyophilized feces), it is an example of liquid solid extraction. If the extraction involves two 
liquid phases, it is an example of liquid-liquid extraction. 
1.7.1. Precipitation: 
  This technique mainly depends on precipitation of matrix protein. The acids like trichloro 
acetic acid and perchloric acid or solvents like methanol and acetonitrile are used in various 
proportions to precipitate the proteins. This method is not advisable for LC-MS / GC-MS 
methods. 
Procedure 
a. In case of acids: Take 0.5 to 1.0 ml of plasma/serum/urine and add 100 to 200µl of 10 to 
20 % perchloric acid or trichloroacetic acid or sometimes decreasing the volume and 
increasing the percentage of acid are also recommended. 
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b. In case of solvents: Take 0.5 to 1.0 ml of plasma and add 0.5 to 2.0ml of solvent           
methanol or acetonitrile. 
               After adding the acid or solvent vortex the vial for complete precipitation of protein 
then centrifuge and inject the supernatant. It is recommended to filter the sample whenever the 
technique is used to avoid clogging of the column. 
1.7.2. Liquid solid extraction: 
Liquid solid extractions occur between a solid phase and a liquid phase; either phase may 
initially contain the drug substance. Amongst the solids that have been used successfully in the 
extraction (usually via absorption) of drugs from liquid samples are XAD-2 resin, charcoal, 
alumina, silica gel, and aluminum silicate. Sometimes the drugs are contained in a solid phase, 
such as in lyophilized specimen. Liquid solid extraction is often particularly suitable for polar 
compounds that would otherwise tend to remain in the aqueous phase. The method could also be 
useful for amphoteric compounds that cannot be extracted easily from water. 
Factor governing the absorption and elution of drugs from the resin column include 
solvent polarity; flow rate of the solvent through the column, and the degree of contact of the 
solvent within the resin beds. 
          In the absorption process, the hydrophobic portion of the solute that has little affinity for 
the water phase is preferentially adsorbed on the resin surface while the hydrophilic portion of 
the solute remains in the aqueous phase. Alterations in the lipophilic/hydrophilic balance within 
the solute or solvent mix, and not within the resin affect adsorption of the solute. 
        Biological samples can be prepared for clean up by passing the sample through the resin 
bed where drug (metabolite) components are adsorbed and finally eluted with an appropriate 
solvent. 
          The liquid solid extraction method provides a convenient isolation procedure for blood 
samples, thus avoiding solvent extraction, protein precipitation, drug looses and emulsion 
formation. It is possible; however, that strong drug protein binding could prevent sufficient 
adsorption of drug to resin. 
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1.7.3. Dehydration method: 
  An aqueous biological sample is treated with sufficient quantity of anhydrous salt 
(sodium or magnesium sulfate) to create a “dried” mix. This mix is then extracted with a suitable 
organic solvent to remove the desired drug or metabolite. 
1.7.4. Liquid – Liquid Extraction: 
Liquid-liquid extraction is probably the most widely used technique because  
 The analyst can remove a drug or metabolite from larger concentrations of 
endogenous material that might interfere with the final analytical determination. 
 The technique is simple, rapid and has a relatively small cost factor per sample. 
 Extract containing the drug can be evaporated to dryness, and the residue can be 
redissolved in a smaller volume of more appropriate solvent. In this manner, sample 
becomes more compatible with a particular analytic methodology in the measurement 
step such as mobile phase in HPLC determination. 
 The extracted material can be redissolved in small volumes (e.g. 100 to 500 µL of 
solvent), thereby extending the sensitivity limit of an assay. 
 It is possible to extract more than one sample concurrently.  
 Near quantitative recoveries (90 % or better) of most drugs can be obtain through 
multiple or continuous extractions. 
            Partitioning (p) or distribution of a drug between two possible liquid phases can be 
express in terms of partition or distribution coefficient, usually called P.A. partition coefficient is 
constant only for a particular solute, temperature and pair of solvent used. 
         By knowing the P value for the extracted drug and the absolute volume of two phases to be 
utilized, the quantity of drug extracted after single extraction can be obtain. In multiple 
extractions methodology, the original biologic sample is extracted several times with fresh 
volume of organic solvent until as much drug as possible is obtained. Because the combine 
extracts now contain the total extracted drug, it is desirable to calculate the number of extraction 
necessary to achieve maximum extraction.
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 1.8. ESTIMATION OF DRUGS IN BIOLOGICAL SAMPLE BY HPLC 
Most of the drugs in biological sample were analyzed by HPLC method because many 
advantages like rapidity, specificity, accuracy, and precision, ease of automation and elimination 
tedious extraction and isolation procedure. Some of the advantages are: 
 Speed (analysis can be completed in 20 min or less) 
 Greater sensitivity (various detectors can be employed) 
 Improved resolution (wide variety of stationary phase) 
 Reusable column (expensive columns but can be used for many Samples) 
 Ideal for the substances of low volatility, 
 Easy sample recovery, handling and maintenance, 
 Instrumentation leads itself to automation and quantization (less time and less labor) 
 Precise and reproducible, 
 Calculation are done by integrator itself and  
 Suitable for preparative liquid chromatography on a much larger scale. 
            There are different models of separation in HPLC. They are normal phase mode, reverse 
phase mode reversed phase ion pair chromatography, ion exchange chromatography, affinity 
chromatography and size exclusion chromatography (gel permeation and gel filtration 
chromatography). 
           In normal phase mode, the nature of stationary phase is polar and mobile phase is 
nonpolar .in this technique nonpolar compound travel faster and are eluted first because of lower 
affinity between the nonpolar compound and the stationary phase. Polar compound are retains 
for longer time and take more time to elute because of their higher affinity with the stationary 
phase. So the normal phase mode of separation is not generally used for pharmaceutical 
application because most of the drug molecules are polar in nature hence take longer time to 
elute. 
           Reversed phase mode was the most popular mode for analytical and preparative 
separation of compound of interest in chemical, biological, pharmaceutical, food and biomedical 
sciences. In this mode, the stationary phase was nonpolar hydrophobic packing with octyl or octa 
decyl functional group bonded to silica gel and mobile phase is a polar solvent. An aqueous 
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mobile phase uses secondary solute chemical equilibrium (such as ionization control, ion 
suppression, ion pairing and complexation) to control retention selectivity. The polar compound 
gets eluted first in this mode and nonpolar compound are retained for longer time. As most of the 
drug and pharmaceuticals are polar in nature, they are not retained for longer time and hence 
elute faster. The different columns used are octa decyl silane (ODS) or C18, C8, C4 etc., 
(depending upon the increasing polarity of the stationary phase). 
           The various component of HPLC are pumps (solvent delivery system), mixing unit, 
gradient controller and solvent degasser, injector (manual or auto), guard column, analytical 
column, detector, recorder, and /or integrators. Recent models are equipped with computers and 
software for data acquisition and processing. 
The choice of the column should be made after a careful consideration of the mode of the 
chromatographic technique. Three types of column are available based upon types of packing 
and particle size, namely, rigid solid, hard gels, and porous and peculiar layer beds, the column 
of smaller particles (3-10µ) are always preferred because they offer high efficiency(number of 
theoretical plates /meter) and speed of analysis. 
          The different types of detection used in HPLC method based on ultraviolet (UV), 
fluorescence, refractive index, mass spectrophotometric detector or a diode array detector (DAD) 
Chemical derivatization procedure for HPLC are performed in order to improve delectability, to 
improved selectivity (or specificity), to modify the chromatographic properties, and in some 
cases to provide favorable mass spectral fragmentation pattern for structural elucidation when a 
mass spectrometer is used either as an off or on line detector. 
         Methods for analyzing drug in biological sample can be developed, provided one who has 
knowledge about the nature of the sample, namely, its molecular weight, polarity, ionic 
character, and solubility parameter. An exact recipe for HPLC however cannot be provided 
because method development involves considerable trial and error procedure. The most difficult 
problem arising is where to start, what type of column is worth trying with type of mobile phase. 
In general one begins with reverse phase chromatography, when the compounds that are 
hydrophilic in nature with many polar groups and are water soluble. 
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         The organic phase, that concentration required for the mobile phase can be estimated by 
gradient elution method. For aqueous sample mixtures, the best method is gradient reversed 
phase chromatography. Gradient can be started with 5-10% organic phase in the mobile phase 
and the organic phase concentration (acetonitrile or methanol) can be increased up to 100% 
within 20-30 min. Separation was optimized by changing the initial mobile phase composition 
and slope of gradient according to the chromatogram obtained from preliminary run. The initial 
mobile phase composition has been estimated on the basis of where the compounds of interest 
were eluted, namely, at what mobile phase composition. 
          Elution of drug molecules can be altered by changing the polarity of mobile phase. The 
elution strength of mobile phase depends upon its polarity, the stronger the polarity, higher is the 
elution. Ionic sample (acidic or basic) can be separated; if they are present in undissociated form. 
Dissociation of ionic sample may be suppressed by proper selection of pH. 
            The pH of mobile phase has to be selected in such a way that the compounds are not 
ionized. If the retention time is too short, the decrease of mobile phase concentration in the 
mobile phase can be in steps of 5%. If the retention times are too long, an increased in 5% steps 
of the organic phase concentration is needed. 
        Whenever acidic or basic are to be separated it is strongly advisable to control mobile phase 
pH by adding a buffer, pH of the buffer be adjusted before adding organic phase. The buffer 
selected for a particular separation should be use to control pH over the range of ≈ pKa ± 1.0 the 
buffer should transit light at or below 220 nm so as to allow low UV detection. 
          Optimization can be started only after the reasonable chromatogram has been obtained. A 
reasonable chromatogram means that the entire compounds are detected by more or less 
symmetrical peaks on the chromatogram. By a slight change in mobile phase composition, the 
shifting of the peaks can be expected. From a few experimental measurements, the position of 
the peaks can be predicted within the range of investigated changes. An optimizing 
chromatogram is the one in which all the peaks were symmetrical and well separated in less run 
time.  
        The peak resolution was increased by using a more efficient column (column with high 
theoretical plate number, N), which can be achieve by using a column of smaller particle size, or 
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a longer column these factor, however will increased the analysis time. Flow rate does not 
influence the resolution, but it has a strong effect on the analysis time. 
       The parameter that are affected by the changes in chromatographic condition are, 
 Resolution (Rs) 
 Capacity factor(K‟), 
 Selectivity (α), 
 Column efficiency (N) and  
 Peak asymmetry Factor (As). 
1.8.1. Quantitative Analysis by HPLC 
 Three methods are generally used for quantitative analysis in HPLC. They are the 
external standard method, the internal standard method and standard addition method. 
 External standard method  
 The external standard method involves the use of single standard or up to three standard 
solutions. So the peak area or the height of the sample and the standard used are compared 
directly or the slope of calibration curved based on standards that contain known concentration 
of the compound of interest. 
 Internal standard method  
 A widely used technique involves the addition of an internal standard to the analytes for 
compensating various analytical errors. In this approach, a known compound of a fix 
concentration is added to the known amount of sample to give separate peak in the 
chromatograms, to compensate for the losses of the compound of interest during sample 
pretreatment steps. Any loss of the compound of interest will be compromised by the loss of an 
equivalent fraction of internal standard. The accuracy of this approach obviously depends on the 
structural equivalence of the compounds of interest and the internal standard 
8, 9
.   
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Method Validation Requirements for Example (ICH) 
[10, 11] 
 
 
 
   Precision
 
          Assay repeatability                                                       ≤ 1% RSD 
          Intermediate precision (Ruggedness)                          ≤ 2% RSD 
   Accuracy 
          Mean recovery per concentration                           100.0% ±2.0% 
    Limit of detection 
          Signal to-to-noise ratio                                                      ≥ 3:1 
   Limit of quantification   
          Signal to-to-noise ratio                                                     ≥ 10:1 
    Linearity/Range 
           Correlation coefficient                                                     >0.99 
           y-Intercept                                                                       ± 10% 
            Visual                                                                              Linear 
     Robustness 
          System suitability                                                               yes 
           Solution stability                                 ± 2% change from time zero 
     Specificity 
      Resolution from main peak                            >2 min. (retention  time)               
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2. REVIEW OF LITERATURE 
12-29 
 
Jayaseelan et al 
12
 (2010) have reported the new analytical method development and 
validation for the simultaneous estimation of Lamuvidine and Stavudine in tablet dosage form by 
RP-HPLC Method by using reverse-phase  C18 SYMMETRY column with mobile phase of 
methanol and water (80:20v/v) with UV detection at 266nm and flow rate is 1.5ml/min. 
Kumar et al 
13 
(2010) have reported the method development and validation of RP-HPLC 
method for simultaneous determination of Lamivudine and Zidovudine using Altima C18 
(150*4.6mm) pre packed column, filtered and degassed Ammonium acetate buffer: Methanol 
(80:20) as mobile phase and flow rate is 1.0ml/min and effluent was monitored at 270nm.  
Rajesh and Pooja et al 
14
 (2010) have reported the Validated RP-HPLC method for 
simultaneous estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in a tablet dosage 
form using Luna C18 column (25 cm*4.60 mm, particle size 5µm), mobile phase is acetonitrile: 
potassium dihydrogen phosphate buffer (pH 3.0 ± 0.05 adjusted with orthophosphoricacid); 
triethylamine (70:30:0.5 v/v), flow rate is 1.5ml/min with UV detection at 260nm. 
Jayaseelan et al 
15
 (2010) have reported the Bio analytical method development and 
validation of Lamivudine by RP-HPLC method using C18 column (250mm*4.6mm, 5µm particle 
size), mobile phase is methanol: water (85:15v/v) with UV detection at 270nm and flow rate is 
1.0ml/min. 
Malipatil et al 
16
 (2009) have reported the determination of Tenofovir Disoproxil 
Fumarate by a sensitive simple isocratic RP-HPLC method using Luna C18 column 
(250mm*4.6mm, 5µm), mobile phase is 0.1%formic acid: acetonitrile (50:50), flow rate is 
0.8ml/min with UV detection is 305nm. 
Pawan et al 
17
 (2009) have reported the development and validation of a HPLC method 
for the simultaneous analysis of Abacavir sulphate and Lamivudine in combined tablet dosage 
form using Waters Nova-pak HR silica column 300mm length, mobile phase is acetic acid 
(0.2%v/v): methanol with UV detection at 254nm and flow rate is 2ml/min. 
Sagar et al 
18 
(2009) have reported the stability indicating ion-pair RP-HPLC method for 
estimation of Tenofovir Disoproxil Fumarate in tablet dosage forms using C18(250 
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mm*4mm,5µm), mobile phase is acetonitrile: 0:01M TBAHS (50:50%v/v), flow rate is 
1.0ml/min and UV detection is 210nm. 
Anandakumar et al 
19
(2009)  have reported the validated RP-HPLC method for 
simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Pure and in 
Tablet Dosage Form using Luna C18 column (150 mm*4.6 mm i.d), mobile phase is acetonitrile: 
methanol: water (30:50:20v/v), UV detection at 258nm and flow rate is 0.6ml. 
Patel et al 
20
 (2009) have reported the Spectrophtometric Method Development and 
Validation for Simultaneous Estimation of Tenofovir Disoproxil Fumarate and Emtricitabine in 
Bulk Drug and Tablet Dosage form by performing two methods, first method is formation and 
solving of simultaneous equation method using 259 nm and 286 nm and second method is 
absorption ratio method which uses at 286 nm and 247.6 nm 
Seloi and Isadore et al 
21 
(2009) have reported the Rapid method for the quantitative 
determination of Efavirenz in human plasma using C18 column (2, 5µm, 150mm*2.0mm i.d) 
mobile phase is 0.1Mformic acid: acetonitrile: methanol (43:52:5) flow rate is 0.3ml/min with 
UV detection at 247nm and 275nm. 
Eda et al 
22
 (2009) have reported the Development and validation of a reverse-phase 
HPLC method for analysis of Efavirenz and its related substances in the drug substances and in a 
capsule formulation using column Zorbax SB CN (15 cm*4.6mm i.d), mobile phase 90%water, 
with 0.05% trifluoroacetic acid/10%methanol, flow rate is 1.5ml/min with UV detection at 
250nm. 
Philippe Morin et al 
23
, (2005); have reported the method involved a quantitative 
recovery of these drugs from rat plasma by solid-phase extraction on Oasis HLB Waters 
cartridges followed by optimised HPLC separation on an Atlantis dC18 column with acetic acid–
hydroxylamine buffer (ionic strength 5 mM, pH 7)-acetonitrile elution gradient. Quantitation was 
performed by HPLC/UV at 260 nm. Finally, a new buffer, obtained with acetic acid and 
hydroxylamine, has been tested in HPLC/ESI-MS/MS and appears to be an efficient volatile 
buffer in the medium 5–7 pH range. Indeed, at pH 7 and low ionic strength (5 mM), its buffer 
capacity is one hundred times higher to that obtained for the usual acetic acid/ammonia buffer. 
Appala Raju et al
24
,(2008); have reported a simultaneous stability indicating RP-HPLC 
method is developed for the estimation of Emtricitabine, Tenofovir Disoproxil fumerate and 
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Efavirenz in tablet dosage form. Chromatography was carried on an Inertsil ODS 3V column 
using gradient composition of 0.02M sodium dihydrogen orthophosphaste as mobile phase A and 
mixture of Methanol and water in ratio of 85:15 as mobile phase B at a flow rate of 1.5 ml/min 
with detection at 265 nm. The retention times of the Emtricitabine, Tenofovir disoproxil 
fumerate and Efavirenz was about 5.875, 8.800 and 12.020 min respectively.  
Suresh et al
25, 
(2010); have reported a simple, accurate, precise and sensitive HPLC 
method with UV detection was developed and validated to separate and detected Lamivudine (3-
TC) and Stavudine (internal standard) were extracted from human plasma using methanol protein 
precipitation and were chromatographed on a Phenomenex C18 column using 20μl injection 
volume and detection at 270nm.An isocratic mobile phase consisting of Methanol: Water 
(85:15%v/v) was used to separate these drugs. The absolute recoveries of 3-TC was greater than 
90% were achieved. The described method can be readily utilized for analysis of pharmaceutical 
products. 
Rajesh Sharma et al
26
 (2009); have reported a simple, rapid reversed-phase high 
performance liquid chromatographic method had been developed and validated for estimation of 
emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. The estimation was 
carried out on Luna C18 column with a mixture of acetonitrile: potassium dihydrogen phosphate 
buffer (pH 3.0 ± 0.05 adjusted with orthophosphoric acid): triethylamine in the ratio of 
70:30:0.5(v/v) as mobile phase. UV detection was performed at 260 nm. The retention time was 
1.78 and 2.27min. For emtricitabine and tenofovir disoproxil fumarate respectively and total run 
time was 4 min. at a flow rate of 1.5 mL min-1. The high percentage of recovery and low 
percentage coefficient of variance confirm the suitability of the method for the simultaneous 
estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. 
Eunice Kazue Kano et al
27 
By (HPLC) method with ultraviolet detection was developed 
to quantificate lamivudine (3-TC) in human plasma samples from bioequivalence studies. 3-TC 
and stavudine (internal standard, I.S.) were extracted from 0.5 ml of human plasma by 
acetonitrile protein precipitation. The method was validated over a concentration range of 0.05–
3.00 μg/ml and used in a bioequivalence trial between two lamivudine formulations  
Yadav M et al
28 
; have developed a  selective, sensitive, rugged, and high throughput 
liquid chromatography tandem mass spectrometry method is developed for the determination of 
one nucleotide tenofovir (TFV) and two nucleosides emtricitabine (FTC) and lamivudine (3TC) 
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reverse transcriptase inhibitors in human plasma. Plasma samples were prepared by solid-phase 
extraction of the analytes and acyclovir (ACV) as internal standard using Waters Oasis MCX 
cartridges. The chromatographic separation is achieved in a run-time of 3.0 min on an ACE 5 CN 
column (150 mm × 4.6 mm, 5 μm) under isocratic conditions. The mobile phase consisted of 
0.5% formic acid in water and acetonitrile (55:45, v/v). A linear dynamic range of 4.0-802 
ng/mL, 15.0-3006 ng/mL, and 20.1-4023 ng/mL is established for TFV, FTC, and 3TC, 
respectively, using 0.2 mL plasma sample. It is successfully applied to a bioequivalence study of 
[300(TFV) + 200(FTC) + 300(3TC)] mg tablet formulation in 43 healthy human subjects under 
fasting conditions. 
Anandakumar karunakaran et al
29 
; have developed a simple, rapid reverse - phase 
high performance liquid chromatographic method has been developed and validated for the 
simultaneous estimation of lamivudine and tenofovir disoproxil fumarate in pure and in tablet 
dosage form. The estimation was carried out on a Phenomenex Luna C18 (150 mm x 4.6 mm 
i.d., particle size 5µm) column with a mixture of acetonitrile: methanol: water in the ratio of 
30:50:20 (v/v) as mobile phase. UV detection was performed at 258 nm. The retention time was 
3.27 and 4.15 min. for lamivudine and tenofovir disoproxil fumarate, respectively. The flow rate 
was 1.0 mL min
-1
. The LOD and LOQ values were found to be 0.0099 and 0.0299 mg mL
-
1
 for lamivudine and 0.0328 and 0.0994 mg mL
-1
 for tenofovir disoproxil fumarate, respectively.  
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3.1. AIM AND OBJECTIVE 
Estimation of drugs in biological media is increasingly important nowadays, which 
reveals information like bioavailability, bioequivalence, and pharmacokinetics and drug research. 
HPLC is the most suitable technique for the analysis of biological fluids owing to its well-
developed characteristics and ruggedness. It is an extremely sensitive, precise, accurate, and 
rapid, separation technique. 
From the extensive literature review it was found that very few studies have been 
reported for bio analytical method development and UV spectrophtometric method on Tenofovir 
and Lamivudine.  
LC-MS/MS methods have also been reported, but this expensive apparatus would be not 
cost-effective for clinical routine determination of Tenofovir disproxil fumarate and Lamivudine. 
With the increasing worldwide use of Tenofovir disproxil fumarate and Lamivudine, 
there is an urgent need to develop a simple, rapid, reliable and low-cost analytical method for the 
pharmacokinetic study and clinical routine monitoring. 
Previous authors had used a mobile phase consisting  
Yadav M et al developed a method on liquid chromatography tandem mass spectrometry for the 
determination of one nucleotide tenofovir (TFV) and two nucleosides emtricitabine (FTC) and 
lamivudine (3TC) reverse transcriptase inhibitors in human plasma with mobile phase consisting 
of 0.5% formic acid in water and acetonitrile (55:45, v/v) on CN column (150 mm × 4.6 mm, 5 μm). 
Anandakumar karunakaran et al developed a method on HPLC and validated for the 
simultaneous estimation of lamivudine and tenofovir disoproxil fumarate in pure and in tablet 
dosage form. The estimation was carried out on a Phenomenex Luna C18 (150 mm x 4.6 mm 
i.d., particle size 5µm) column with a mixture of acetonitrile: methanol: water in the ratio of 
30:50:20 (v/v) as mobile phase. 
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HPLC: 
 To develop a specific, sensitive, simple, reliable and widely applicable as well as low-
cost HPLC-UV method in Human plasma.  
 To separate the drug from Human plasma under the most common experimental 
conditions, without adding expensive special equipments.  
 Literature review reveals that the previous authors used 0.5% formic acid in water and 
acetonitrile and acetonitrile: methanol: water. In this view, the present study aim is to 
replace the above acetonitrile combination of solvents by Heptane sulphonic acid and 
acetonitrile. 
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3.2. PLAN OF WORK 
Bioanalytical method development for Lamuvidine and Tenofovir Disoproxil Fumarate: 
The present work is planned into two phases: 
Phase I: 
Optimization of chromatographic conditions 
 Selection of wavelength 
 Selection of initial separation conditions 
 Selection of mobile phase (pH, peak modifier, solvent strength, ratio 
and flow rate) 
 Nature of the stationary phase 
 Estimation of Tenofovir and Lamivudine 
Phase II: 
Validation of the method 
The developed method were proposed to be validated using the various validation parameters 
such as, 
 Accuracy 
 Precision 
 Linearity 
 Limit of detection (LOD) / Limit of quantitation (LOQ) 
 Selectivity / Specificity 
 System suitability. 
 Ruggedness 
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3.3DRUG PROFILE 
Lamivudine
30-31
 
Chemical profile: 
Chemical name : 2', 3'-dideoxy-3'-thiacytidine, commonly called 3TC 
Molecular formula : C8H11N3O3S 
Structure: 
 
 
Fig 1: Structure of lamivudine 
 
Pharmacokinetic data: 
Bioavailability     -  Absolute bioavailability was lies between 64 to 94%. 
Protein binding    -  80 to 86%. 
Half life   -  5 to 7 hours. 
Routes                  -  Oral. 
C max                                - 6 to 12 hours 
Description   : White or almost white powder. 
Solubility   : Freely soluble in water 
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Category: 
Anti retro viral potentnucleoside is reverse transcriptase inhibitor (NRTI). Treat for 
chronic hepatitis B at a lower dose than for treatment of HIV. 
Dose: 
 For 5 mg/ day initially, titrated to response over 7-14 days, then up to a maximum dose of 
10 mg once daily. 
 For adults with HIV the dose is 300mg once daily or 150mg twice a day. 
 For the treatment of adults with hepatitis B, the dose is 100mg once daily. 
 For a child 3 months to 12 years old, about 1.4-2 mg per lb. of body weight twice a day, 
no more than 150 mg per dose. 
Pharmacokinetics 
Absorption 
C max is approximately 1.28 mcg/ml (single dose of 100 mg), T max is 0.5 to 2 h. Absolute 
bioavailability is approximately 87%. 
Distribution 
Less than 36% protein bound. DVD is approximately 1.3 L/kg. 
Metabolism 
Metabolism of Lamivudine is a minor route of elimination. The metabolite is trans-sulfoxide 
metabolite. 
Elimination 
The majority is eliminated unchanged in the urine. Mean half-life is 5 to 7 h. Cl is approximately 
398.5 ml/min. 
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Pharmacological profile 
Mechanism of action: 
 Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse 
transcriptase and also the reverse transcriptase of hepatitis B. It is phosphorylated to active 
metabolites that will compete for incorporation into viral DNA. They inhibit the HIV enzyme 
competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the 
nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for 
DNA chain elongation, and therefore, the viral DNA growth is terminated. 
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TENOFOVIR DISOPROXIL FUMARATE
32-33
 
Chemical profile: 
Chemical name : ({[(2R)-1-(6-amino-9H-purin-9-yl) propan-2-yl]oxy}methyl) phosphonic 
Acid. 
Molecular formula :C9H14N5O4P
  
= 287.213 g/mol 
Structure: 
 
Fig 2: Structure of Tenofovir Disoproxil fumarate 
 
Pharmacokinetic data:  
Bioavailability   -  25% 
Protein binding   -  >99.5%. 
Half life   -   17 hours. 
Routes                -  Oral and intravenous. 
C max                          -  0.5 to 1 hours 
Description        : A white powder 
Solubility      : Freely soluble in water, slightly soluble in methanol. 
Category              : Antiretroviral 
Volume of distribution : Approximately 500 litter indicating additional tissue binding. 
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Pharmacology 
Tenofovir disoproxil fumarate is a prodrug of tenofovir that inhibits the activity of HIV-1 reverse 
transcriptase and hepatitis B virus (HBV) polymerase by competing with deoxyadenosine 5′-
triphosphate and by DNA chain termination after incorporation into DNA. 
Pharmacokinetics 
Absorption 
Tenofovir C max is approximately 0.3 mcg/mL and AUC is approximately 2.29 mcg/ml. T max is 
approximately 1 h, and bioavailability is approximately 25%. Administration following a high-
fat meal increases the oral bioavailability, with an increase in AUC of approximately 40% and an 
increase in C max of approximately 14%. 
Distribution 
Vd of tenofovir is approximately 1.3 L/kg. Binding to plasma or serum proteins is less than 0.7% 
and 7.2%, respectively. 
Metabolism 
Tenofovir is not a CYP-450 substrate. 
Elimination 
Elimination of tenofovir is by glomerular filtration and tubular secretion. Approximately 70% to 
80% is recovered in urine as unchanged drug. Elimination half-life is approximately 17 h. 
Indications and Usage 
Treatment of HIV-1 infection in adults and children 12 y of age and older in combination 
with other antiretroviral agents; treatment of chronic hepatitis B infection in adults. 
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Pharmacological profile 
Mechanism of action: 
Before phosphorylation, tenofovir disoproxil fumarate is converted to tenofovir in the 
intestinal lumen and plasma by diester hydrolysis. Tenofovir is then internalized into cells, 
possibly by endocytosis, and subsequently phosphorylated in sequential steps to tenofovir 
monophosphate and to the active metabolite, tenofovir diphosphate. In a mechanism similar to 
that of NRTIs, tenofovir diphosphate competes with its natural nucleotide counterpart, 
deoxyadenosine 5´-triphosphate, for incorporation into newly forming HIV DNA. Once 
successfully incorporated, termination of the elongating DNA chain ensues, and DNA synthesis 
is interrupted. Although the end results of tenofovir activity is similar to that of the NRTIs, subtle 
differences exist between this class of drugs and tenofovir. Like tenofovir, NRTIs also must be 
phosphorylated to active metabolites to inhibit reverse transcription of RNA into DNA. 
However, since tenofovir already contains a phosphonate group attached to the adenine base, the 
initial addition of a phosphate group is circumvented; thus, only two steps are required in the 
phosphorylation of tenofovir, as opposed to three with the NRTI class. As the initial 
phosphorylation step is potentially a limiting factor in the activation of NRTIs in resting 
CD4
+
 cells and macrophages, tenofovir may result in better antiviral activity than NRTIs in cells 
that have limited proliferative and phosphorylative capacity. 
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3.4 METHODOLOGY
 
A. Materials and instrument used: 
a) Drug sample & Study products: 
Standard drug of Lamivudine and Tenofovir Disoproxil Fumarate were procured from 
Hetero Drugs Limited, Hyderabad.  Andhra Pradesh, India. 
Plasma : Blank plasma was collected from Kovai Medical Center and Hospitals, Coimbatore. 
b) Chemicals and solvents used for estimation: 
 HPLC Water (HPLC Grade)              - Qualigens, Mumbai, India. 
 Acetonitrile (HPLC Grade)              -  Rankem, Mumbai, India. 
 Methanol (HPLC Grade)               -  Finar, Ahmadabad, India. 
 Heptane sulphonic acid (HPLC Grade)     -  Otto Kemi Ltd, Mumbai. 
 Orthophosphoric acid (AR Grade)         -  SD fine chem. Ltd, Mumbai. 
 
c) Instruments used: 
 Elico pH meter LI 127. 
 Shimadzu LC-20 AT HPLC. 
 SPD-M20A Prominence diode array detector. 
 Shimadzu 1600 LC-UV Spectrophotometer. 
 Sonica ultrasonic cleaner. 
 Solvent filtration unit – Millipore. 
 Shimadzu electronic balance AY 220. 
 Ultra cooling centrifuge – Remi, India 
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B.OPTIMIZATION OF CHROMATOGRAPHIC CONDITION FOR THE 
ESTIMATION OF LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE 
a) Selection of wavelength 
An UV spectrum of 10 µg/ml Lamivudine in water and Tenofovir Disoproxil Fumarate in 
methanol was recorded by scanning in the range of 200 nm to 400 nm. From the UV 
spectrum, it was observed that Lamivudine has 272 nm and Tenofovir Disoproxil Fumarate 
has 259 nm as suitable wavelength. 
b) Selection of chromatographic method 
Selection of proper chromatographic method depends on the nature of the sample or its 
properties like ionic/ionizable/neutral character, its molecular weight and solubility. The drug 
selected for the present study is Polar in nature hence, reverse phase HPLC or ion-pair or 
ion–exchange chromatography method must be used. Because of its simplicity and suitability 
for initial separations reverse phase method was selected. 
c) Initial chromatographic conditions for separation of Lamivudine and Tenofovir 
Disoproxil Fumarate 
Standard solution: 
10μg/ml of Lamivudine and Tenofovir Disoproxil Fumarate was dissolved in 10 ml of 
HPLC grade water. 
Equipment 
System          :       Shimadzu gradient HPLC 
Pump            :        LC – 20AT prominence solvent 
Delivery system 
Detector        :       SPD-M20A Prominence Diode array Detector 
Injector         :       Rheodyne 7725i with 20μl loop 
Chromatographic conditions 1 
Stationary phase : Phenomenex C18 column. 
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Mobile phase            :          Solvent A: Triethylamine buffer 5mM 
pH 3.5 (adjusted with Orthophosphoric acid) 
Solvent B: Acetonitrile 
Solvent ratio         :       50:50(A: B) 
Wavelength of 
Detection            :           259 nm. 
Flow rate                   :          1.0ml/min. 
Sample size               :          20µl. 
Needle wash              :        HPLC grade water. 
Temperature         :         Room temperature (25
0
C) 
At the above chromatographic conditions Lamivudine was eluted at the retention time 
of 18.2min. The peak observed was broad and asymmetric, thus not selected for further 
studies. Tenofovir was not eluted. 
Chromatographic condition 2 
Stationary phase  :           Phenomenex C18 Column 
Mobile phase   :          Solvent A: Triethylamine 5mM pH 4 
(adjusted with Orthophosphoric acid) 
Solvent B: Acetonitrile 
Solvent ratio              :            80:20 (A: B) 
Detection            :           259 nm 
Flow rate  :           1.0 ml/min 
Sample size                :            20µl. 
Needle wash               :            HPLC grade water. 
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Temperature               :            Room temperature (25
0
C) 
Lamivudine was eluted at retention time of 17.1 minute with peak splitting 
and fronting and Tenofovir was eluted at retention time of 11.1minute with broad 
peak hence not selected for further method development. 
Chromatographic condition 3 
Stationary phase :    Phenomenex C18 Column 
            Mobile phase              :           Solvent A: ammonium acetate buffer 20Mm pH    
                                                            3.5(adjust with Orthophosphoric acid)  
                                                            Solvent B: Acetonitrile 
Solvent ratio   :  50:50 
Detection   :  259 nm 
 Flow rate   :  1.0 ml/min 
Sample size    :  20 μl 
Needle wash    :  water HPLC grade 
Column temperature   :  room temperature (25ºC). 
The retention time of Lamivudine was found to be 12.1min and that of Tenofovir was 
found to be 8.4min. The peak observed was broad and the retention time of both drugs not 
close to each other, so the peak separation is high observed. 
 
Chromatographic condition 4 
Stationary phase   :   Phenomenex C18 Column 
Mobile phase           :   Solvent A: Heptane sulphonic acid 0.05% pH 
                                                      2.5 (adjusted with Orthophosphoric acid) 
                                                      Solvent B: Acetonitrile 
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Solvent ratio          :   80:20(A: B) 
Detection    :   259 nm 
Flow rate       :   1.0 ml/min 
Sample size                   :   20µl. 
Temperature                  :   Room temperature (25
0
C) 
Retention time Tenofovir was found to be 4.5min and Lamivudine was found to be 
9.6min.  Broad peaks with tailing observed for both the drugs. 
Chromatographic condition 5 
Stationary phase    :   Phenomenex C18 Column 
Mobile phase         :   Solvent A: Heptane sulphonic acid 0.05% 
            PH 3.0 (adjusted with Orthophosphoric acid) 
                                                       Solvent B: Acetonitrile 
Solvent ratio           :   80:20(A: B) 
Wavelength   of 
Detection     :   259 nm 
Flow rate          :  1.0 ml/min 
Sample size                    :  20µl. 
Temperature                   :  Room temperature (25
0
C) 
Tenofovir was eluted at 4.8 min and Lamivudine at 8.1min with perfect peak properties, 
hence selected for further studies. 
d) Effect of pH 
Using 20% of acetonitrile and buffer solution of different pH ranging from 3.5, 4.5, 5.5 
at 272 nm, the standard solution was run up to 20 min at a flow rate of 1.0 ml/min. The 
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retention time of Tenofovir was 5.6, 4.9, 4.1 minutes respectively. For the present study, a pH 
of 3.0 was selected as the chromatogram obtained with this pH was symmetrical in shape. 
e) Effect of ratio of mobile phase 
Heptane sulphonic acid and acetonitrile with 70:30, 75:25 and 80:20 ratios were used as the 
mobile phase. At 80:20 ratios, symmetric peaks were eluted at 4.2 min and 8.9 min for 
Tenofovir and Lamivudine respectively. At 70:30 and 75:25 ratios the peaks were 
asymmetrical in shape. Thus for the present study 80:20 ratio of Heptane sulphonic acid and 
acetonitrile was selected as the mobile phase. 
f) Effect of flow rate 
Keeping the mobile phase ratio at (80:20, v/v) Heptane sulphonic acid: acetonitrile, the 
chromatograms were recorded at a flow rate of 0.5ml/min, 1.0ml/min 1.5ml/min. At flow rate 
of`1.0ml/min, the peaks were sharp and separated with good resolution. Hence, 1ml/min was 
kept constant for the present analysis. 
 
 
 
 
 
g) Fixed chromatographic conditions 
The following chromatographic conditions were used for the estimation of Tenofovir and 
Lamivudine in human plasma. 
Stationary phase      :     Phenomenex C18 Column 
Mobile phase                   :     Solvent A: Heptane sulphonic acid 0.05% 
    PH 3.0 (adjusted with Orthophosphoric acid) 
    Solvent B: Acetonitrile 
Solvent ratio                     :      80:20(A: B) 
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Detection       :      259 nm 
Flow rate       :      1.0 ml/min 
Sample size                      :      20µl. 
Temperature                     :      Room temperature (25
0
C) 
Pretreatment method for biological fluid: 
Method of sample preparation is an important criteria for biological samples. For the present 
study plasma was obtained from Clinical Laboratory Services of KMCH Hospital, 
Coimbatore. Protein precipitation method was selected for the present study.  
Protein precipitation 
This method is the most commonly used method for the extraction of analytes from 
biological fluids. In this method precipitating agents like acetonitrile, methanol mixture of 
acetonitrile-methanol etc was added to the blank plasma to precipitate the proteins present in 
the plasma and then the precipitate formed was removed by filtration or centrifugation. The 
supernatant resulted is directly injected into HPLC column without any further treatment and 
chromatograms were recorded. 
An aliquot of 0.1ml of plasma in a glass tube 0.05ml of standard solution, 0.05ml of internal 
standard solution and 0.2 ml of mixture of acetonitrile-methanol in the ratio of (80:20,v/v) 
was added and then centrifuged for 15 minutes at 5000 rpm. The same extraction procedure 
was also repeated by using methanol and acetonitrile separately for extraction of drug from 
plasma and the percentage recovery was calculated for all the precipitating agents.  
The chromatograms of plasma extracted with acetonitrile, methanol and mixture of 
acetonitrile- methanol (80:20, v/v) were recorded using the fixed chromatographic conditions. 
The chromatogram of blank plasma without any drug was also recorded. Based up on the 
percentage recovery acetonitrile-methanol mixture (80:20, v/v) was selected for the present 
study because of its higher percentage recovery.  
Preparation of standard stock solution: Stock solution of Lamivudine and Tenofovir 
1mg/ml were prepared separately by dissolving 10mg of each drug in 10ml standard flasks 
and the volume was made up to 10 ml with the mobile phase.  
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Working standards  
From the stock solution working standard solutions of 100µg/ml was prepared by diluting 
1ml to 10ml with mobile phase. Further solutions were made by from the above solution by 
diluting 0.8ml, 1.6ml, 3.2ml, 4.8ml, 6.4ml, and 8.0ml standard solutions to 10ml in a standard 
flask with mobile phase. An aliquot of 0.05ml from these working standards were taken in 
serial 10ml standard flasks to effect concentrations of 100, 200, 400, 600, 800 and 1000ng/ml 
respectively. 
Preparation of standard graph: 
Preparation of calibration standards 
To 0.1ml of blank plasma 0.05ml of Lamivudine and 0.05ml of Tenofovir were added to get 
concentration of 100, 200, 400, 600, 800 and 1000ng/ml respectively. To these calibration 
standards 0.2ml of precipitating agent mixture of acetonitrile-methanol (80:20, v/v) was 
added and then centrifuged for 15 minutes at 5000 rpm. After centrifugation the clear 
supernatant liquid was collected and a quantity of 20µl was injected into the HPLC column 
and chromatograms were recorded. Standard calibration graph was plotted using ratio of peak 
area of Lamivudine and tenofovir to its concentration. 
ESTIMATION OF LAMIVUDINE AND TENOFOVIR IN HUMAN PLASMA: 
Recording the chromatogram  
The optimized chromatographic conditions were maintained to record the chromatograms of 
the calibration standards Lamivudine and Tenofovir of and sample from a clinical study. 
First, baseline stabilization was done for about 20 minutes. Then standard solutions, 
calibration standard solutions and sample from clinical study containing Lamivudine and 
Tenofovir were injected and chromatograms were recorded. 
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4. RESULTS AND DISCUSSION 
Bioanalytical method was developed for Tenofovir and Lamivudine and it was validated for its 
transferability. 
Chromatographic Conditions  
     Acetonitrile: Methanol (80:20) was selected as good separating agent for Tenofovir and 
Lamivudine, since it showed maximum recovery in comparison with acetonitrile or methanol 
(Table1&2). The chromatogram was recorded for the standard calibration and plasma sample 
under developed chromatographic conditions. The retention time of Tenofovir is 4.6 minutes and 
that of Lamivudine is 8.1 minutes respectively. The chromatogram was well resolved without 
any interference from one another. Moreover, peaks not showed any tailing or fronting. The 
concentration of Tenofovir and Lamivudine in Human plasma was determined from the 
calibration of the spiked plasma by regression analysis. It showed very good linearity in the 
range of 200-1000 ng/ml for Tenofovir, the r
2
 value was found to be 0.998 (Fig. 3) and that of 
Lamivudine was found to be 200 to 1000ng/ml, the r
2
 value was found to be 0.998 (Fig .4). 
The peaks obtained in the present study were symmetric, good and no interference was observed 
between the peaks. 
The method developed was advantageous than the reported methods by its lesser precision 
values and increased accuracy values. The run time of 10 minutes makes the method rapid and 
economical than the previously reported methods. 
The extraction method used for the present study was simple and newer than previous methods. 
In most of the reported methods used for plasma for extraction of drug was protein precipitated 
with acetonitrile but, for present method acetonitrile –methanol mixture was selected because of 
its maximum recovery of drug from plasma and it is advantageous. 
 
 
 
 
Dept of Pharmaceutical Analysis                                                              Results and Discussion 
 
KMCH College Of Pharmacy Page 36 
 
Table: 1 Recovery study of Tenofovir 
Levels 
 
 
Conc. of 
Drug 
added 
(ng/ml) 
 
 
Amount of drug 
recovered in 
plasma sample 
(ng/ml) 
 
(%) Recovery 
 
Methanol ACN Methanol CAN 
 
Level – I 
 
200 
 
 
192.3 
 
 
 
195.4 
 
 
96.15 
 
 
97.7 
 
Level –II 
 
400 
 
 
386.5 
 
 
383.7 
 
 
96.67 
 
 
95.92 
 
Level III 
 
500 
 
491.05 
 
 
486.5 
 
98.21 
 
97.3 
                 
 
Table: 2 Recovery study of Lamivudine 
                      
 
 
 
 
 
 
 
 
 
                       
Levels 
 
 
Conc. of 
Drug 
added 
(ng/ml) 
 
 
Amount of drug 
recovered in plasma 
sample 
(ng/ml) 
 
(%) Recovery 
 
Methanol ACN Methanol CAN 
 
Level – I 
 
200 
 
 
194.6 
 
 
196.1 
 
 
97.3 
 
 
98.05 
 
Level –II 
 
400 
 
 
376.3 
 
 
380.3 
 
 
94.07 
 
 
90.15 
 
Level III 
 
500 
 
484.3 
 
481.6 
 
96.86 
 
96.38 
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Table.3 Peak area of calibration curve for Tenofovir 
 
 
 
 
Fig: 3 Calibration curve for Tenofovir 
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Table.4 peak area of calibration curve for Lamivudine 
 
Concentration ng/ml 
 
Peak area 
 
0 
 
0 
 
200 
 
19211 
 
400 
 
38322 
 
600 
 
57534 
 
800 
 
75845 
 
1000 
 
96056 
 
                               
Fig: 4 Calibration curve for Lamivudine 
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4.1 VALIDATION OF THE METHOD 
 Accuracy and precision 
     The accuracy and precision study was performed at two levels intra-day and inter-day. The 
developed method showed good accuracy and precision (Table5 to 8). The intra-day accuracy of 
Tenofovir was range between 95.02% and 100.28% with precision between 0.0192 and 0.0401, 
the inter-day accuracy range of Tenofovir between 97.01% and 99.78% with precision between 
0.0193 and 0.0412. The intra-day accuracy of Lamivudine range was between 96.45% and 
99.86% with precision between 0.0166 and 0.0389, the inter-day accuracy of Lamivudine range 
between 95.64% and 98.77% with precision between 0.0167 and 0.2153. 
       Table: 5 Accuracy and Precision Studies of Tenofovir (Intra - Day) 
       
 
S. No. 
 
Conc. of       
Drug (ng/ml) 
 
Mean 
concentration 
Found (ng/ml) 
 
 
Accuracy 
(%) 
 
Precision 
(%) 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
200 
 
400 
 
600 
 
800 
 
1000 
 
198.2 
 
          385.0 
          
         585.7  
 
         782.1 
 
         975.7 
 
 
96.13  
 
96.42  
 
97.61 
 
97.76 
 
97.57 
 
 
0.040  
 
0.028  
 
0.019  
 
0.013  
 
0.018 
            *n=6 (Mean of 6 values) 
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         Table: 6 Accuracy and Precision Studies of Tenofovir (Inter - Day) 
       
 
S. No. 
 
Conc. of       
Drug (ng/ml) 
 
Mean 
concentration 
Found (ng/ml) 
 
 
Accuracy 
(%) 
 
Precision 
(%) 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
200 
 
400 
 
600 
 
800 
 
1000 
 
       189.1  
 
       381.8  
 
       569.5  
 
       793.1  
 
       961.2 
 
 
94.55 
 
95.45  
 
94.91  
 
99.13 
 
      96.12 
 
 
0.044  
 
0.019  
 
0.031  
 
0.018  
 
0.023 
       *n=6 (Mean of 6 values) 
 
Table: 7 Accuracy and Precision Studies of Lamivudine (Intra - Day) 
       
 
S. No. 
 
Conc. of       
Drug (ng/ml) 
 
Mean 
concentration 
Found (ng/ml) 
 
 
Accuracy 
(%) 
 
Precision 
(%) 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
200 
 
400 
 
600 
 
800 
 
1000 
 
191.8 
 
390.1 
          
         581.5 
 
         779.3 
 
         979.4 
 
 
95.9  
 
97.52  
 
96.91 
 
97.14 
 
97.94 
 
 
0.016 
 
0.028  
 
0.037  
 
0.029  
 
0.031 
              *n=6 (Mean of 6 values) 
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Table: 8 Accuracy and Precision Studies of Lamivudine (Inter - Day) 
       
 
S. No. 
 
Conc. of       
Drug (ng/ml) 
 
Mean 
concentration 
Found (ng/ml) 
 
 
Accuracy 
(%) 
 
Precision 
(%) 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
200 
 
400 
 
600 
 
800 
 
1000 
 
183.01 
 
376.02 
          
         575.5 
 
         786.3 
 
         973.7 
 
 
91.05  
 
94.05  
 
95.91 
 
98.28 
 
97.03 
 
0.017 
 
0.215  
 
0.139 
 
0.061 
 
0.071 
            *n=6 (Mean of 6 values) 
       
Linearity and range 
              According to ICH guidelines, the method proved to be linear between 200-1000 ng/ml 
for Tenofovir, with a correlation equation y =9.950x – 4.523, correlation coefficient   was   > 
0.999 (fig.3). The linearity range for Lamivudine was between 200-1000 ng/ml, with a 
correlation equation y =95.62 x –14.14, correlation coefficient   was   > 0.999 (fig.4). 
Limit of Detection and Limit of Quantification  
                The limit of quantification (LOQ) and limit of detection (LOD) of Tenofovir was 
found to be 311.55 ng/ml, 102.81ng/ml and Lamivudine was found to be 32.48, 10.71ng/ml 
respectively. 
Recovery from plasma 
      The extraction efficiency of Tenofovir from Human plasma at the concentrations of 200, 400, 
and 500ng/ml was found to be 95.02%, 98.90% and 100.28%.  The extraction efficiency of 
Lamivudine from Human plasma at the concentrations of 200, 400 and 500 ng/ml was found to 
be 95.7%, 96.92% and 98.3%. The results of recovery studies are shown in Table.9 and 10. 
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Table: 9 Recovery study for extraction method 
Levels 
 
 
Conc. of 
Drug added 
(ng .ml) 
 
 
Amount of 
drug 
recovered in 
plasma sample 
(ng /ml) 
 
Relative 
Recovery 
(%) 
 
 
 
  %RSD 
 
 
 
 
Level – I 
 
200 192.3 95.02      8.6 
 
Level –II 
 
400 386.5 98.90 7.9 
 
Level III 
 
500 491.05 100.28 7.3 
            *n=6 (Mean of 6 values) 
 
Table: 10 Recovery studies of Lamivudine 
Levels 
 
 
Conc. of 
Drug added 
(ng .ml) 
 
 
Amount of 
drug 
recovered in 
plasma sample 
(ng /ml) 
 
Relative 
Recovery 
(%) 
%RSD 
 
Level – I 
 
400 382.52 95.62 8.9 
 
Level –II 
 
800 771.77 96.47 9.3 
 
Level III 
 
1000 1583.02 98.93 8.5 
              *n=6 (Mean of 6 values) 
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    System suitability 
System suitability parameters such as column efficiency (theoretical plates), resolution 
factor and peak asymmetry factor of the optimized methods were found satisfactory. The results 
of stability are shown in Table 10 and 11. 
                                      
Table: 11 System suitability studies 
S. No. Parameters Tenofovir 
1 Theoretical Plate 12438.76 
2 Tailing Factor 0.958 
3 HETP 12.059 
4 LOD 102.81ng/ml 
5 LOQ 311.55ng/ml 
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Table: 12 System suitability studies 
S. No. Parameters Lamivudine 
1 Theoretical Plate 654.76 
2 Tailing Factor 0.944 
3 HETP 22.93 
4 LOD 10.71 ng/ml 
5 LOQ 32.48ng/ml 
 
Ruggedness 
   It expresses the precision within laboratories variations like different days, different 
analyst, and different equipments. Ruggedness of the method was assessed by spiking the 
standard 6 times in two different days with different analyst and the reports are shown in Table 
13. 
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Table :13 Ruggedness studies 
  
Drug Concentration 
µgm/ml 
Mean Peak area %RSD 
DAY I Analyst-1 
Lamivudine 200µg/ml 19211.1 0.46 
Tenofovir 200µg/ml 1998.4 0.14 
DAY 2 Analyst-2 
Lamivudine 200µg/ml 19244.2 0.42 
Tenofovir 200µg/ml 1997.9 0.32 
          *n=6 (Mean of 6 values) 
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D:\tenofovir\Blank plasma (80 20 Heptane, acn) 129.lcd 
Acquired by: K.M.C.H College of pharmacy 
Sample Name: Blank plasma 
Sample ID: Test 
Vail #: 
Injection Volume: 20 ul 
Data File Name Blank plasma (80 20 Heptane, acn) 129.lcd 
Method File Name: Lamivudine & Tenofovir.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 8/30/2011 1:22:03 PM 
Data Processed: 2/15/2012 11:32:12 AM 
 
<Chromatogram> 
D:\tenofovir\ Blank plasma (80 20 Heptane, acn) 129.lcd 
 
Fig: 2 Chromatogram of blank plasma 
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D:\lab solutions\STD, tenofovir & Lamivudine (80 20 hept, acn) ph 3 030.lcd 
Acquired by: K.M.C.H College of pharmacy 
Sample Name: combo 
Sample ID: Standard 
Vail #: 
Injection Volume: 20 ul 
Data File Name: tenofovir & Lamivudine (STD) (80 20 hept, acn) ph 3 030.lcd 
Method File Name: lamivudine.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/18/2012 1:06:59 PM 
Data Processed: 2/18/2012 4:24:05 PM 
 
<Chromatogram> 
 
D:\lab solutions\STD, Tenofovir & Lamivudine 100 µg/ml (80 20 hept, acn) ph 3 030.lcd 
 
 
Fig: 3 Chromatogram of Tenofovir and Lamivudine 100µg/ml 
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D:\lab solutions\STD, Tenofovir & Lamivudine (80 20 hept, acn) ph 3 124.lcd 
Acquired by: K.M.C.H College of pharmacy 
Sample Name: lamuvidine ph 3 
Sample ID: Standard 
Vail #: 
Injection Volume: 20 ul 
Data File Name: Tenofovir & Lamivudine (STD) 10µg/ml (80 20 hept, acn) ph 3 124.lcd 
Method File Name: lamivudine.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/19/2012 2:36:59 PM 
Data Processed: 2/19/2012 4:04:05 PM 
 
<Chromatogram> 
 
D:\lab solutions\STD, Tenofovir & Lamivudine 10µg/ml (80 20 hept, acn) ph 3 124.lcd 
 
 
Fig: 5 Chromatogram of Tenofovir and Lamivudine 10µg/ml 
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C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 018.lcd 
Acquired by: KMCH College of pharmacy 
Sample Name: plasma acn meth sample ph 3 
Sample ID: Sample 
Injection Volume: 20 ul 
Data File Name: spiked plasma 200ng.lcd 
Method File Name: fsdf.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/21/2012 10:18:51 AM 
Data Processed: 2/21/2012 10:57:50 AM 
---------------------------------------------------------------------------------------------------------------- 
<Chromatogram> 
 
C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 018.lcd 
 
Fig: 10 Chromatogram of Tenofovir and Lamivudine in plasma 200ng/ml 
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C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 020.lcd 
Acquired by: KMCH College of pharmacy 
Sample Name: plasma acn meth sample ph 3 
Sample ID: Sample 
Injection Volume: 20 ul 
Data File Name: spiked plasma 400ng.lcd 
Method File Name: fsdf.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/21/2012 11:11:51 AM 
Data Processed: 2/21/2012 12:17:50 AM 
---------------------------------------------------------------------------------------------------------------- 
<Chromatogram> 
 
C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 020.lcd 
 
 
Fig: 10 Chromatogram of Tenofovir and Lamivudine in plasma 400ng/ml 
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C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 024.lcd 
Acquired by: KMCH College of pharmacy 
Sample Name: plasma acn meth sample ph 3 
Sample ID: Sample 
Injection Volume: 20 ul 
Data File Name: spiked plasma 800ng.lcd 
Method File Name: sample.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/21/2012 1:18:51 PM 
Data Processed: 2/21/2012 2:57:50 PM 
---------------------------------------------------------------------------------------------------------------- 
<Chromatogram> 
 
C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 024.lcd 
 
 
 
Fig: 10 Chromatogram of Tenofovir and Lamivudine in plasma 600ng/ml 
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C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 027.lcd 
Acquired by: KMCH College of pharmacy 
Sample Name: plasma acn meth sample ph 3 
Sample ID: Sample 
Injection Volume: 20 ul 
Data File Name: spiked plasma 1000ng.lcd 
Method File Name: sample.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/21/2012 03:8:54 PM 
Data Processed: 2/21/2012 03:56:51 PM 
---------------------------------------------------------------------------------------------------------------- 
<Chromatogram> 
 
C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 027.lcd 
 
 
Fig: 10 Chromatogram of Tenofovir and Lamivudine in plasma 800ng/ml 
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C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 030.lcd 
Acquired by: KMCH College of pharmacy 
Sample Name: plasma acn meth sample ph 3 
Sample ID: Sample 
Injection Volume: 20 ul 
Data File Name: spiked plasma 1000ng.lcd 
Method File Name: sample.lcm 
Batch File Name: 
Report File Name: Default.lcr 
Data Acquired: 2/21/2012 04:10:14 PM 
Data Processed: 2/21/2012 04:57:50 PM 
---------------------------------------------------------------------------------------------------------------- 
<Chromatogram> 
 
C:\Documents and Settings\Administrator\Desktop\New Folder (2)\sample 030.lcd 
 
Fig: 10 Chromatogram of Tenofovir and Lamivudine in plasma 1000ng/ml 
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UV SPECTRUM 
 
UV spectrum of standard Tenofovir 
 
 
 
 
UV spectrum of  plasma matches with Tenofovir spectrum 
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UV spectrum of standard Lamivudine 
 
 
UV spectrum of plasma matches with Lamivudine 
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PEAK PURITY GRAPHS 
 
Fig: 16 Peak purity of standard Tenofovir 
 
 
Fig: 17  Peak purity of Tenofovir in  plasma 
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Peak purity of Lamivudine in plasma 
Peak profile 
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5. SUMMARY AND CONCLUSION 
A bioanalytical method was developed for the estimation of Lamivudine and Tenofovir 
Disoproxil Fumarate by HPLC method. The method was validated for its transferability to other 
user or other laboratory. The HPLC method developed by using Heptane sulphonic acid with pH 
3.0 adjusted with orthophosphoric acid and acetonitrile in meticulous ratio. The peaks obtained 
for the drugs of interest by the present method are well resolved from each other without any 
interference and from the plasma endogenous proteins. The peaks are symmetrical with 
acceptable tailing factor. The retention time of Lamivudine and Tenofovir Disoproxil Fumarate 
was shorter and proves the method is rapid. 
The results of linearity, intraday and interday precision study and capability of the extraction 
method were within the limits of bioanalytical method development. The method was linear with 
a correlation coefficient of acceptable agreement, which is suitable for the estimation of 
Lamivudine and Tenofovir Disoproxil Fumarate in human plasma and other biological fluids. 
The method demonstrated relative recoveries with acceptable relative standard deviation. The 
limit of quantification (LOQ) and limit of detection (LOD) for Lamivudine and Tenofovir 
Disoproxil Fumarate was found to be micrograms lesser than unity. Hence the developed method 
is sensitive for the estimation of Lamivudine and Tenofovir Disoproxil Fumarate in trace 
amounts. 
Peak purity studies, with peak purity index values closer to unity reveals that the method 
developed was specific for the estimation of Lamivudine and Tenofovir Disoproxil Fumarate in 
blood and other biological fluids. 
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